US Court Rules Liquidia's Yutrepia Infringes Patent, Shares Drop Nearly 50%
Shares of Liquidia Corporation fell nearly 50% after a US federal court ruled that its lung drug Yutrepia infringes two claims of United Therapeutics' patent related to treating pulmonary hypertension-associated interstitial lung disease. The ruling impacts Yutrepia's commercial prospects and strengthens United Therapeutics' competing drug Tyvaso's legal protection. Liquidia plans to appeal and seek FDA approval to remove the PH-ILD indication from Yutrepia's label. A final judgment on remedies is expected within a week.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is negative (35/100). Lens Score 47/100.
Outlets measured: economictimes, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (35–35/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 30 Sept, 08:26 pm. Other outlets followed.